Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov 1;4(11):e2134254.
doi: 10.1001/jamanetworkopen.2021.34254.

Pivotal Evaluation of an Artificial Intelligence System for Autonomous Detection of Referrable and Vision-Threatening Diabetic Retinopathy

Collaborators, Affiliations
Clinical Trial

Pivotal Evaluation of an Artificial Intelligence System for Autonomous Detection of Referrable and Vision-Threatening Diabetic Retinopathy

Eli Ipp et al. JAMA Netw Open. .

Erratum in

  • Error in Figure 2.
    [No authors listed] [No authors listed] JAMA Netw Open. 2021 Dec 1;4(12):e2144317. doi: 10.1001/jamanetworkopen.2021.44317. JAMA Netw Open. 2021. PMID: 34935926 Free PMC article. No abstract available.

Abstract

Importance: Diabetic retinopathy (DR) is a leading cause of blindness in adults worldwide. Early detection and intervention can prevent blindness; however, many patients do not receive their recommended annual diabetic eye examinations, primarily owing to limited access.

Objective: To evaluate the safety and accuracy of an artificial intelligence (AI) system (the EyeArt Automated DR Detection System, version 2.1.0) in detecting both more-than-mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR).

Design, setting, and participants: A prospective multicenter cross-sectional diagnostic study was preregistered (NCT03112005) and conducted from April 17, 2017, to May 30, 2018. A total of 942 individuals aged 18 years or older who had diabetes gave consent to participate at 15 primary care and eye care facilities. Data analysis was performed from February 14 to July 10, 2019.

Interventions: Retinal imaging for the autonomous AI system and Early Treatment Diabetic Retinopathy Study (ETDRS) reference standard determination.

Main outcomes and measures: Primary outcome measures included the sensitivity and specificity of the AI system in identifying participants' eyes with mtmDR and/or vtDR by 2-field undilated fundus photography vs a rigorous clinical reference standard comprising reading center grading of 4 wide-field dilated images using the ETDRS severity scale. Secondary outcome measures included the evaluation of imageability, dilated-if-needed analysis, enrichment correction analysis, worst-case imputation, and safety outcomes.

Results: Of 942 consenting individuals, 893 patients (1786 eyes) met the inclusion criteria and completed the study protocol. The population included 449 men (50.3%). Mean (SD) participant age was 53.9 (15.2) years (median, 56; range, 18-88 years), 655 were White (73.3%), and 206 had type 1 diabetes (23.1%). Sensitivity and specificity of the AI system were high in detecting mtmDR (sensitivity: 95.5%; 95% CI, 92.4%-98.5% and specificity: 85.0%; 95% CI, 82.6%-87.4%) and vtDR (sensitivity: 95.1%; 95% CI, 90.1%-100% and specificity: 89.0%; 95% CI, 87.0%-91.1%) without dilation. Imageability was high without dilation, with the AI system able to grade 87.4% (95% CI, 85.2%-89.6%) of the eyes with reading center grades. When eyes with ungradable results were dilated per the protocol, the imageability improved to 97.4% (95% CI, 96.4%-98.5%), with the sensitivity and specificity being similar. After correcting for enrichment, the mtmDR specificity increased to 87.8% (95% CI, 86.3%-89.5%) and the sensitivity remained similar; for vtDR, both sensitivity (97.0%; 95% CI, 91.2%-100%) and specificity (90.1%; 95% CI, 89.4%-91.5%) improved.

Conclusions and relevance: This prospective multicenter cross-sectional diagnostic study noted safety and accuracy with use of the EyeArt Automated DR Detection System in detecting both mtmDR and, for the first time, vtDR, without physician assistance. These findings suggest that improved access to accurate, reliable diabetic eye examinations may increase adherence to recommended annual screenings and allow for accelerated referral of patients identified as having vtDR.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ipp reported receiving grants from Eyenuk Inc for the conduct of the study and grants from Genentech and Norris foundations outside the submitted work. Dr Bode reported receiving grants from Atlanta Diabetes Associates during the conduct of the study. Dr Shah reported receiving grants from Eyenuk Inc for the conduct of the study; grants from Sanofi US, Dexcom, Insulet, NovoNordisk, Eli Lilly, vTv Therapeutics, and Abbott; speaker’s fee from Insulet; and honoraria for serving on the advisory boards of Sanofi US and Medscape outside the submitted work. Dr Silverstein reported buying financial interest in Eyenuk Inc after the study was complete and after the study data were submitted to the US Food and Drug Administration (FDA). Dr Regillo reported receiving grants from Mid Atlantic Retina for the conduct of the study. Dr Lim reported receiving personal fees from Eyenuk Inc as a consultant after the study was completed and after the study data were submitted to the FDA; personal fees from Genentech/Roche, Novartis, Kodiak, Iveric, Cognition, Opthea DMC, Luxa DMC, Unity, Santen DMC, Quark DMC, Aura Biosciences DMC, and Alcon outside the submitted work; and grants from Regeneron, Chengdu, Stealth, Graybug, Aldeyra, NGM, and Clearside outside the submitted work. Dr Sadda reported receiving personal fees from Optos, Centervue, Heidelberg, Topcon, Carl Zeiss Meditec, Nidek, Amgen, Allergan, Apellis, Iveric, Oxurion, Roche/Genentech, Novartis, and 4dMT outside the submitted work. Dr Gray reported receiving personal fees from Eyenuk Inc for supporting design and analysis of the study; Zeiss Inc, and Optovue Inc, and personal payment from Jeffrey Luttrull, MD, outside the submitted work. Dr Bhaskaranand reported being an employee of and has a financial interest in Eyenuk Inc; in addition, Dr Bhaskaranand had patents 9008391, 9002085, 8885901, 8879813, and 11051693 issued to Eyenuk Inc. Dr Ramachandra is an employee of and has a financial interest in Eyenuk Inc; in addition, Dr Ramachandra had patents for 9008391, 9002085, 8885901, 8879813, and 11051693 issued to Eyenuk Inc. Dr Solanki is an employee of and has a financial interest in Eyenuk Inc; in addition, Dr Solanki had patents 9008391, 9002085, 8885901, 8879813, and 11051693 issued to Eyenuk Inc. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Study Procedures in the Prospective Multicenter Cross-Sectional Diagnostic Study of the EyeArt Automated Diabetic Retinopathy Detection System
The clinical reference standard was determined using 4-wide field stereoscopic dilated fundus photographs. The retinal coverage of the four 45-degree field of view images is equivalent to that of 7-field Early Treatment Diabetic Retinopathy Study images (30-degree field of view). Only 1 photograph from each stereo pair for the 4 retinal fields and anterior view is shown. R indicates right eye; L, left eye; ANT, anterior. 1W, 2W, 4W, and 5W are the nasal, central, superior, and inferior fields of the 4-wide field photography protocol, respectively. EyeArt is an artificial intelligence system for autonomous detection of more-than-mild diabetic retinopathy and vision-threatening diabetic retinopathy.
Figure 2.
Figure 2.. Flow Diagram for Participant Disposition in the Prospective Multicenter Cross-Sectional Diagnostic Study of the EyeArt Automated Diabetic Retinopathy Detection System
Final disposition of participants included in more-than-mild diabetic retinopathy (mtmDR) (A) and vision-threatening diabetic retinopathy (vtDR) (B) analyses.AI indicates artificial intelligence.

Similar articles

Cited by

References

    1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. . IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50. doi:10.1016/j.diabres.2017.03.024 - DOI - PubMed
    1. Yau JW, Rogers SL, Kawasaki R, et al. ; Meta-analysis for Eye Disease (META-EYE) Study Group . Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564. doi:10.2337/dc11-1909 - DOI - PMC - PubMed
    1. Flaxel CJAR, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA. Diabetic retinopathy preferred practice pattern. Ophthalmology. 2020;127(1):66-P145. doi:10.1016/j.ophtha.2019.09.025 - DOI - PubMed
    1. International Federation on Ageing . International Agency for the Prevention of Blindness; International Diabetes Federation. The Diabetic Retinopathy Barometer Report Global Findings. Accessed October 1, 2021. https://www.iapb.org/wp-content/uploads/DR-Global-Report-1.pdf
    1. Centers for Disease Control and Prevention . Diabetes Report Card 2017. US Dept of Health and Human Services; 2018.

Publication types

MeSH terms

  NODES
admin 1
COMMUNITY 1
INTERN 5
Note 1
twitter 2